{"meshTagsMajor":["Precision Medicine","Xenograft Model Antitumor Assays"],"meshTags":["Heterografts","Transplantation, Heterologous","Melanoma","Precision Medicine","Mice","Animals","Xenograft Model Antitumor Assays","Humans"],"meshMinor":["Heterografts","Transplantation, Heterologous","Melanoma","Mice","Animals","Humans"],"organisms":["10095"],"publicationTypes":["Comment","Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov\u0027t"],"abstract":"Targeted therapies have advanced the treatment options for cutaneous melanoma, but many patients will progress on drug. Patient-derived xenografts (PDX) can be used to recapitulate therapy-resistant tumors. Furthermore, PDX modeling can be utilized in combination with targeted sequencing and phosphoproteomic platforms, providing preclinical basis for second-line targeted inhibitor strategies. See related article by Krepler et al., p. 1592.","title":"Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.","pubmedId":"26842234"}